QUCY
Quantum Cyber·NASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About QUCY
Quantum Cyber N.V.
A molecular genetics cancer diagnostics company
200 Connecticut Ave. Suite 400
Norwalk CT 06854
Provides diagnostic services for cancer.
Quantum Cyber N.V. was incorporated in the Netherlands on March 8, 2021. The company is a molecular genetics cancer diagnostic company established in 2021 to acquire PharmGenomics GmbH with the aim of commercializing its product portfolio in Europe and the United States. The company focuses on the diagnostic side of the cancer industry. The company competes with other entities that develop and offer diagnostic tests to detect the presence of cancer. The company's core product is the CRC screening stool DNA test, and they are in the early stages of researching a similar test for pancreatic cancer.
Company Financials
EPS
QUCY has released its 2023 Q4 earnings. EPS was reported at -0.25, versus the expected -0.25, meeting expectations. The chart below visualizes how QUCY has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
